03 Profile
Vital Signsby Bridgehead
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Diabetes
Dr Stella Sarraf: no photograph is held, so the sector leader plate is shown instead.
Sector leader
Dr Stella Sarraf
Chief Executive Officer and Founder, Spinogenix
1
0
Oct 2026Nov 2026to date
1
press citation on 1 topic since 9 Oct 2026 · last quoted 9 Oct 2026
02 Quoted on · 1 of 29 topics
Dr Stella Sarraf: key facts
- Kind of voice
- Sector leader
- Role
- Chief Executive Officer and Founder, Spinogenix
- Quoted on
- Diabetes
- Tracked press citations
- 1
- Most recently quoted
- 9 Oct 2026
04 The signal · where Dr Stella Sarraf sits on diabetes
Ranked 45= of 100 voices quoted in the press on diabetes, level with 55 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1
Douglas TwenefourClinicianHead of Clinical, Diabetes UK11 - 2
Helen KnightRegulatorDirector of Medicines Evaluation, National Institute for Health and Care Excellence (NICE)9 - 3
Parth NarendranAcademicProfessor of Diabetes Medicine; Honorary Consultant Physician (leads the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital Birmingham), University of Birmingham7 - 45=William HsuAcademicendocrinologist and chief health officer for biotech company L-Nutra1
- 45=Dr Robert WeinrebAcademicChair and Distinguished Professor of Ophthalmology at University of California, San Diego1
- 45=Dr Stella SarrafSector leaderChief Executive Officer and Founder, Spinogenix1
- 45=Subrata BasuClinicianClinical director, Central Basildon PCN (Dr)1
- 45=Ahmad HaidarAcademicalgorithm developer1
Showing the leaders and the ranks around 45=, of 100 voices · See every voice on the topic →
05 On the record · press
What Dr Stella Sarraf has said
By outlet · linked articles
- drugtargetreview.com1
Where Dr Stella Sarraf has been quoted
- 01Tazbentetol shows retinal neuroprotection potential in diabetic mouse modeldrugtargetreview.com · 9 Oct 2026
Verbatim
“These findings further validate tazbentetol's potential to protect retinal neurons in diseases characterised by early synapse loss. For the millions of people affected by vision loss due to diabetic retinal disease, there remains a significant need for treatments that address the underlying drivers of disease progression. We are encouraged by this data, demonstrating that synaptic restoration can potentially play a significant role in disease management.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- First UK patient treated with NICE approved TeplizumabUniversity of Birmingham
- Branding update for insulin pensDiabetes Research & Wellness Foundation
- DRWF Events: Register now for Diabetes: A Whole Life BlueprintDiabetes Research & Wellness Foundation
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.